MAPK3 and autoimmune polyendocrinopathy: We next treated neutrophils cultured in the presence of APS‐IgG with specific AKT, ERK1/2 and p38 MAPK pathway inhibitors to assess their role in the induction of APS‐IgG‐mediated NET release.